0001493152-20-010243.txt : 20200601 0001493152-20-010243.hdr.sgml : 20200601 20200601133750 ACCESSION NUMBER: 0001493152-20-010243 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200528 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20200601 DATE AS OF CHANGE: 20200601 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OncBioMune Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001362703 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202590810 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52218 FILM NUMBER: 20932583 BUSINESS ADDRESS: STREET 1: 8000 INNOVATION PARK STREET 2: DR, BATON ROUGE CITY: BATON ROUGE STATE: LA ZIP: 70820 BUSINESS PHONE: 225-578-7555 MAIL ADDRESS: STREET 1: 8000 INNOVATION PARK STREET 2: DR, BATON ROUGE CITY: BATON ROUGE STATE: LA ZIP: 70820 FORMER COMPANY: FORMER CONFORMED NAME: QUINT MEDIA INC. DATE OF NAME CHANGE: 20130807 FORMER COMPANY: FORMER CONFORMED NAME: PediatRx Inc. DATE OF NAME CHANGE: 20101230 FORMER COMPANY: FORMER CONFORMED NAME: Striker Energy Corp DATE OF NAME CHANGE: 20060515 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 28, 2020

ONCBIOMUNE PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-52218	20-2590810
(State or other jurisdiction	(Commission	(I.R.S. Employer
of incorporation)	File Number)	Identification No.)

11441 Industriplex Blvd.

Suite 190

Baton Rouge, LA 70809

(Address of principal executive offices)

(225) 227-2384

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [X]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On May 28, 2020, the Board of Directors (the “Board”) of OncBioMune Pharmaceuticals, Inc., a Nevada corporation (the “Company”), appointed Mr. Andrew Kucharchuk as a director of the Company, effective immediately. Mr. Kucharchuk has served as the Company’s Chief Financial Officer since 2009 and as its Chief Executive Officer since November 2019.

Mr. Kucharchuk has no family relationships with any director, executive officer, or person nominated or chosen by the Company to become a director or executive officer of the Company. Mr. Kucharchuk is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K other than his employment agreement with the Company, which is described in the Company’s Annual Report on Form 10-K filed on March 25, 2020. Mr. Kucharchuk has not been, and is not currently expected to be, appointed to any committees of the Board.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ONCBIOMUNE PHARMACEUTICALS, INC.

	By:	/s/ Andrew Kucharchuk
	Name:	Andrew Kucharchuk
	Title:	Chief Executive Officer, Chief Financial Officer and President

Date: June 1, 2020